Abstract: This application provides a carrier configuration method and a communication apparatus. The method may include: a terminal device accesses a first cell by using a control channel resource of a first carrier. The terminal device receives first carrier configuration information in the first cell. The first carrier configuration information is used to change a carrier of the terminal device from the first carrier to a second carrier in the first cell. The first carrier and the second carrier share the control channel resource, and include different spectrum resources. According to this application, spectrum resource utilization of the first cell can be improved.

Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.

Abstract: A rocker arm mechanism of an engine, a system and a method for two-stroke engine brake are provided. The rocker arm mechanism includes a first rocker arm, a second rocker arm and a connection mechanism. One end of the first rocker arm and one end of the second rocker arm is rotatably connected to a shaft, the other end of the first rocker arm is close to a valve of the engine, while the other end of the second rocker arm is close to a cam. The connection mechanism includes a connecting piston and a linkage mechanism. The connecting piston is disposed in the first rocker arm or the second rocker arm, the linkage mechanism is rotatably connected to one end of the connecting piston. The rocker arm mechanism may be used for engine cylinder deactivation and engine brake.

Abstract: A transient electromagnetic device with variable shape and turns includes squares, a transmitting coil carrying frame, a transmitting coil, a turns-variable device, a current generator and a working power supply. The transmitting coil carrying frame is arranged inside the transmitting coil; the transmitting coil carrying frame is configured as a carrier of the transmitting coil, and configured for adjusting a side length of the transmitting coil and a shape of the transmitting coil; the square is configured for clamping and connecting the transmitting coil and the transmitting coil carrying frame to fix the transmitting coil to the transmitting coil carrying frame. The current generator is configured for generating transient current; the turns-variable device is configured for changing the turns of the transmitting coil; and the transmitting coil is configured for transmitting the transient current to a target area to be measured.

Abstract: A follow-hold switch circuit comprising: a follower; a sampling sub-circuit for voltage sampling; a bootstrap-control sub-circuit, which provides a bootstrap voltage to the sampling sub-circuit when the circuit is in a following state; a sampling-switch-control sub-circuit, which provides a common-mode voltage to a bootstrap capacitor in the bootstrap-control sub-circuit when the circuit is in a holding state; the follower is connected to an output of the sampling sub-circuit; the sampling sub-circuit is connected to the bootstrap-control sub-circuit and the sampling-switch-control sub-circuit respectively through a sampling switch; the present disclosure can effectively improve the linearity of sampling switches.

Abstract: A distributed recording system includes a first device and one or more second devices. The first device sends a distributed recording instruction, to control the one or more second devices to perform recording. The one or more second devices send audio data obtained through recording to an upper-layer recording application.

Abstract: An audio control method, a system, and device, the method including displaying, by a first device, in response to a first user operation, a candidate device list, obtaining, in response the user selecting a second device from the candidate device list, an audio capability parameter of the second device indicating a hardware capability and a software capability for playing audio, determining a first audio play policy based on the audio capability parameter of the second device, obtaining second audio data by the first device by performing first processing on first audio data from a first audio application according to the first audio play policy, and sending, by the first device, the second audio data to the second device, so that second device plays the second audio data or processes the second audio data and plays processed second audio data.

Abstract: A terminal, includes: multiple antenna ports, configured to connect antennas; a first determining unit, configured to determine a power scaling factor and indication information, and determine capability information of the terminal according to the power scaling factor and the indication information; a sending unit, configured to receive the capability information and send the capability information to a network device; a second determining unit, configured to determine a actual uplink transmission power of the terminal according to feedback information of the network device and the capability information.

Abstract: This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses.

Abstract: A method for catalytically synthesizing furaneol, which uses a specific peptide to function as a catalyst, uses rhamnose to function as a raw material, and uses an organic solvent and a phosphate buffer to function as a reaction solvent to be co-heated to prepare furaneol.

Abstract: Aspects of the disclosure provide an integrated circuit that includes a first memory controller, a second memory controller and at least a functional circuit coupled to the second memory controller. The first memory controller is configured to control memory access to a first memory. The second memory controller is configured to control memory access to a second memory that is able to be turned on/off. The functional circuit is configured to operate based on the second memory. The second memory controller is configured to cause the second memory to be turned on when an application requires an operation of the functional circuit.

Abstract: A method and a device for playback of a presentation slide are provided. The method may include receiving uploaded presentation slides to be played back, and converting the presentation slides into slides in video format. The conversion may be performed according to a preset order. Further, a user operation on a speaker client may be detected. A presentation slide corresponding to the user operation may be substantially simultaneously pushed to the speaker client and an audience client. The slide pushed may be the presentation slide converted to the video format. The speaker client and the audience client may substantially simultaneously playback the pushed slide.

Abstract: Methods and mobile terminals for refreshing a page in a browser on a mobile terminal are provided herein. In an exemplary method, an external shake instruction can be received from a user. According to the shake instruction, acceleration values of the mobile terminal can be obtained. When at least one of the acceleration values of the mobile terminal exceeds a preset threshold value, the page in the browser on the mobile terminal can be refreshed.

Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g. asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g. asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.

Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.